Canthaxanthin retinopathy

An investigation by light and electron microscopy and physicochemical analysis
  • B. Daicker
  • K. Schiedt
  • J. J. Adnet
  • P. Bermond
Original Investigations


The eyes of a patient with canthaxanthin retinopathy were obtained at autopsy and examined by light and electron microscopy. Various tissues of one eye were also studied by physicochemical methods. Morphologically, there were red, birefringent, lipid-soluble crystals in the inner layers of the entire retina. They were particularly large and numerous perifoveally, where they were also clinically visible, but they also occurred frequently in a ring-shaped form peripherally and, less frequently, equatorially. The crystals were located in a spongy degeneration of the inner neuropil, where atrophy of the inner parts of the Müller cells was noticed. The compound isolated from the retina was identical with synthetic canthaxanthin according to mass and proton-resonance spectroscopy. Quantitatively, the retina contained up to 42 μg canthaxanthin per gram of tissue besides a minor amount of other carotenoids. Of the other tissues of the eye, only the ciliary body contained measurable concentrations of canthaxanthin. From the great number and size of the crystals, on the one hand, and the relatively small amount of isolated canthaxanthin on the other, it was concluded that the crystals presumably represent a canthaxanthin-lipoprotein complex rather than pure canthaxanthin alone. Examination showed that clinically, only the central portion of the canthaxanthin thesaurismosis, where crystals are packed most densely, can be seen.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bone RA, Landrum JT, Tarsis SL (1985) Preliminary identification of the human macular pigment. Vision Res 25:1531–1535Google Scholar
  2. Boudreault G, Cortin P, Corriveau LA, Rousseau AP, Tardif Y, Malenfant M (1983) Le rétinopathie á la canthaxanthine. 1. Etude clinique de 51 consommateurs. Can J Ophthalmol 18:325–328Google Scholar
  3. Cortin P, Corriveau LA, Rousseau AP, Tardif Y, Malenfant M, Boudreault G (1982) Maculopathie en paillettes d'or. Can J Ophthalmol 17:103–106Google Scholar
  4. Cortin P, Boudreault G, Rousseau AP, Tardif Y, Malenfant M (1984) La rétinopathie á la canthaxanthine. 2. Facteurs prédisposants. Can J Ophthalmol 19:215–219Google Scholar
  5. Daicker B (1978) Die fleckige fettige Degeneration der Netzhautperipherie. Eine Form der „Schneckenspuren“. Graefe's Arch Clin Exp Ophthalmol 205:147–155Google Scholar
  6. Foos RY (1972) Vitreoretinal juncture, topographical variations. Invest Opthalmol 11: 801–809Google Scholar
  7. Franco JL, Adenis JP, Mathon C, Lebraud P (1985) Un nouveau cas de maculopathie en paillettes d'or. Bull Soc Ophthalmol Fr 85:1035–1037Google Scholar
  8. Hennekes R, Weber U, Küchle HJ (1985) Über Canthaxanthinschäden der Netzhaut. Z Prakt Augenheilkd 6:7–9Google Scholar
  9. Jakobiec FA (1982) Ocular anatomy, embryology and teratology. Harper & Row, Philadelphia, p 490Google Scholar
  10. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM (1981) Tamoxifen retinopathy. Ophthalmology 88:83–89Google Scholar
  11. McGuiness R, Beaumont P (1985) Gold dust retinopathy after the ingestion of canthaxanthin to produce skin-bronzing. Med J Aust 143:622–623Google Scholar
  12. Metge P, Maudirac-Bonnefoy C, Bellaube P (1984) Thésaurismose rétinienne à la canthaxanthine. Bull Mem Soc Fr Ophtalmol 95:547–549Google Scholar
  13. Meyer JJ, Bermond P, Pournaras C, Zoganas L (1985) Canthaxanthin. Langzeiteinnahme und Sehfunktionen beim Menschen. Dtsch Apoth Z 125:1053–1057Google Scholar
  14. Philipp W (1985) Carotinoid-Einlagerungen in der Netzhaut. Klin Monatsbl Augenheilkd 187: 439–440Google Scholar
  15. Poh-Fitzpatrick MB, Barbera LG (1984) Absence of crystalline retinopathy after long-term therapy with β-carotene. J Am Acad Dermatol 11:111–113Google Scholar
  16. Puissant A (1984) La carotinodermie et la pilule à bronzer. Journée Ann Nutr Diet (Paris) 25:1–4Google Scholar
  17. Ros AM, Leyon H, Wennersten G (1985) Crystalline retinopathy in patients taking an oral drug containing canthaxanthine. Photodermatology 2:183–185Google Scholar
  18. Rousseau A (1983) Canthaxanthine deposits in the eye. J Am Acad Dermatol 8:123–124Google Scholar
  19. Saraux H, Laroche L (1983) Maculopathie à papillottes d'or après absorption de canthaxanthine. Bull Soc Ophtalmol Fr 83:1273–1275Google Scholar
  20. Tronnier H (1984) Zur Schutzwirkung von β-Carotin und Canthaxanthin gegen UV-Reaktionen der Haut. Z Hautkr 59:859–870Google Scholar
  21. Weber U, Goerz G (1985) Augenschäden durch Carotinoid-Einnahme. Dtsch Ärztebl 82:181–182Google Scholar
  22. Weber U, Goerz G (1986) Carotinoid-Retinopathie. III. Reversibilität. Klin Monatsbl Augenheilkd 188: 20–22Google Scholar
  23. Weber U, Goerz G, Hennekes R (1985a) Carotinoid-Retinopathie. I. Morphologische und funktionelle Befunde. Klin Monatsbl Augenheilkd 186:351–354Google Scholar
  24. Weber U, Hennekes R, Goerz G (1985b) Cartinoid-Retinopathie. II. Elektrophysiologische Befunde bei 23 Carotinoid-behandelten Patienten. Klin Monatsbl Augenheilkd 187:507–511Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • B. Daicker
    • 1
  • K. Schiedt
    • 2
  • J. J. Adnet
    • 3
  • P. Bermond
    • 4
  1. 1.Universitäts AugenklinikBaselSwitzerland
  2. 2.F. Hoffmann-La Roche & Co. Ltd.BaselSwitzerland
  3. 3.Laboratoire Pol BouinCentre Hospitalier UniversitaireReimsFrance
  4. 4.Hôpitaux de ReimsReimsFrance

Personalised recommendations